Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID-19 mild to moderate meta-analysis

Libster, 2020
 
NCT04479163
RCTconvalescent plasma treatmentplaceboCOVID-19 mild to moderatelow
80/80 conclusif
  • demonstrated 48 % decrease in clinical deterioration (PE) with a high degree of certainty due to low risk of bias
PLACID, 2020
 
CTRI/2020/04/024775
RCTconvalescent plasma treatmentstandard of careCOVID-19 mild to moderatehigh
235/229 suggested
  • inconclusive 7 % increase in death or transfer to ICU (PE) but with a low degree of certainty due to high risk of bias
  • suggested 20 % increase in PCR-negative conversion (7-day) but with a low degree of certainty due to high risk of bias

PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).